~~<i id='4B47EDCA1A'><strike id='4B47EDCA1A'><tt id='4B47EDCA1A'><pre id='4B47EDCA1A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

leisure time

author：explore 2025-09-30 12:18:53 - browse：73

An advisory panel to the Food and Drug Administration delivered a split decision on a surgical system used in a controversial blood pressure treatment called renal denervation.

The panel, whose advice the FDA typically follows, voted that the system developed by ReCor Medical was safe and effective. It voted that the benefits of a system developed by Medtronic, however, did not outweigh the risks.

“While this is a very safe procedure, the efficacy was mild at best,” Keith Allen, director of surgical research at St. Luke’s Hospital of Kansas City, said regarding Medtronic’s device.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

hotspot

knowledge

leisure time

entertainment

Wikipedia

explore

AdobeSANFRANCISCO—Almostthreeyearsago,thecountry’sbiggestbankunveiledaloftyplantofixthehealthcareind

WSS

Maisha Meds is a PBM, but don't call it that

HPV vaccine, cervical cancer study delivers historic results

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Update the Apgar Score to remove skin color

White House finalizes ITC's import ban of latest Apple Watches

To bolster infectious disease surveillance, genomics powerhouses team up

explore

leisure time

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Update the Apgar Score to remove skin color

Guidelines to prevent youth baseball injuries need more muscle

Antibiotic resistance and the global rise in human conflict

Medical leaders decry Supreme Court decision on affirmative action

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Duchenne breakthrough therapy leaves behind pioneering families

Chronically ill young patients struggle to find fertility info

DIEP, the 'gold standard' of breast reconstruction, is under threat

Flu vaccine reformulation won't be easy, manufacturers warn

knowledge

CVS is on a mission to consolidate health care. Will it work?

There's an unseen cost to disruptive road

FDA sets aggressive timeline for overhauling inspection procedures

Antibiotic resistance and the global rise in human conflict

UCB departs biotech trade group BIO

New weight loss drugs work. But how can they best be used?

leisure time

entertainment

Wikipedia

explore